Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average PT from Analysts

Zura Bio Limited (NASDAQ:ZURA) has earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $15.80.

Several equities research analysts have recently commented on the company. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Leerink Partners started coverage on Zura Bio in a research report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective for the company. HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a research report on Monday, November 18th. Chardan Capital reduced their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th.

Insiders Place Their Bets

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Someit Sidhu sold 51,728 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total transaction of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This represents a 2.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 22.10% of the company’s stock.

Hedge Funds Weigh In On Zura Bio

Several institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC increased its holdings in shares of Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Zura Bio by 15.8% in the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares in the last quarter. Forefront Analytics LLC grew its stake in shares of Zura Bio by 22.1% in the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after acquiring an additional 7,531 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Zura Bio in the third quarter valued at about $46,000. Finally, AQR Capital Management LLC acquired a new position in shares of Zura Bio in the second quarter valued at about $43,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Stock Performance

Shares of ZURA opened at $2.80 on Friday. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.35. The company has a 50-day moving average price of $4.04 and a two-hundred day moving average price of $3.99.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Analysts expect that Zura Bio will post -0.65 EPS for the current fiscal year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.